Trending News
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- This event has passed.
Hepatitis B&C Training Program and Treatment Update 2019 (October)
October 12, 2019
The Scripps National Hepatitis B & C Training Program and Treatment Update will educate health care practitioners on the prevalence, demographics, natural history, prevention, screening, and diagnosis of chronic viral hepatitis, antiviral therapies, histology, cirrhosis, hepatocellular carcinoma, liver biopsy, referral of patients with chronic HBV and/or HCV infection improving their management, and application of multidisciplinary team approach (local network of practitioners).
Lunch non-CME symposium hosted by AbbVie Inc: MAVYRET: Clinical Data Including Real World Evidence